PARP inhibitor with chemotherapy may improve breast cancer survival by almost 60 percent.
MedPage Today (12/11, Bankhead) reported, "Treatment with a drug that inhibits DNA repair in cancer cells improved breast cancer patients' survival by almost 60 percent when added to conventional chemotherapy," according to results presented at the San Antonio Breast Cancer Symposium. Researchers found that "patients who received the investigational drug BSI-201 in addition to chemotherapy had a median survival of 12.2 months, compared with 7.7 months for chemotherapy alone." The drug works by inhibiting "the nuclear enzyme PARP1, which is involved in multiple cellular processes." The results "confirm and extend" findings "reported at the American Society of Clinical Oncology meeting, when survival was more than nine months with BSI-201 plus chemotherapy, versus less than six months with chemotherapy alone."
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου